Fraud, Waste and Abuse Referrals After a PBM Audit

Most PBM audit findings end with a recoupment demand and a chance to appeal it. Some end differently. When a PBM's audit team concludes that a flagged claim was not simply miscoded but knowingly false, inflated, or fabricated, the file can be referred as a fraud, waste, and abuse (FWA) matter to the plan sponsor's investigations unit, the Medicare Drug Integrity Contractor, a state Medicaid Fraud Control Unit, or federal law enforcement. That referral changes the proceeding. A pharmacy that keeps treating it as a documentation dispute is exposed to False Claims Act liability and OIG exclusion it did not see coming.

From Documentation Gap to FWA Referral

PBM audit teams route a finding to a Special Investigations Unit (SIU), rather than the standard recoupment queue, when the pattern looks intentional: a falsified prior authorization, billing for prescriptions never picked up, or a documentation defect that repeats after the pharmacy was already put on notice. CMS's guidance on Combating Medicare Parts C and D Fraud, Waste, and Abuse directs Part D plan sponsors and their PBMs to report suspected fraud to HHS-OIG, DOJ, or CMS, and to refer matters to the Investigations Medicare Drug Integrity Contractor, currently operated by Qlarant, once a finding rises above a routine billing error. That step usually happens without a hearing, and the pharmacy often learns of it only once the posture on the other side has already changed. Pharmacies still inside the initial response window should start with How to Respond to a PBM Audit Letter: A Step-by-Step Guide.

Recoupment Versus FWA Referral

A recoupment demand is a financial claim: the PBM asserts a dollar figure, and the pharmacy contests it through the audit appeal process, first at the plan sponsor level and, in many state Medicaid matters, before a state hearing officer. An FWA referral moves the same claims onto a different track. Once a Special Investigations Unit, a Medicare Drug Integrity Contractor, or a state Medicaid Fraud Control Unit has the file, intent becomes the operative question, and negotiating a per-claim rate does not resolve it.

Where the Referral Can Go

For claims tied to Medicare Part D or a commercial plan, the referral typically runs from the PBM's SIU to the plan sponsor and then to the Investigations Medicare Drug Integrity Contractor, which can forward evidence of intent to HHS-OIG, the DOJ Civil Division, or the local U.S. Attorney's office. For claims tied to a state Medicaid program, the pathway is set by regulation rather than contract. Under 42 CFR 455.23, once a state Medicaid agency finds a credible allegation of fraud, it must suspend payments to the provider and refer the matter in writing to the state Medicaid Fraud Control Unit (MFCU) by the next business day after the suspension. A pharmacy billing both Medicare Part D and a state Medicaid program on the same claims can face both pathways at once.

Downstream Exposure Once a Matter Is Referred

A confirmed FWA referral carries exposure beyond the disputed claims. Under the False Claims Act (31 U.S.C. § 3729), a knowingly false claim submitted to a federal health care program carries treble damages plus a per-claim civil penalty, pursued by the government directly or by a whistleblower through a qui tam action. Under Section 1128 of the Social Security Act (42 U.S.C. § 1320a-7), OIG can exclude the pharmacy, or an individual pharmacist, from billing Medicare, Medicaid, and every other federal health care program: a mandatory five-year minimum for a program-related fraud conviction, or a discretionary bar short of one. A referral of this kind frequently precedes a network termination action as well, layering a contractual consequence on the regulatory one.

An FWA referral turns the audit from a repayment question into a question about whether the pharmacy keeps billing the program at all.

Why Early Legal Counsel Is Critical

It is critical that pharmacies promptly retain experienced healthcare defense counsel once an audit finding is referred for fraud, waste, or abuse review, or once a subpoena, target letter, or Medicaid Fraud Control Unit notice follows it. Early legal intervention can protect the pharmacy's rights, shape how it responds to the referring agency, avoid statements that read as an admission of intent, and preserve defenses still available before the matter hardens into a civil or criminal posture. Delaying representation until the government has already concluded the pattern was intentional can significantly affect the outcome.

How Health Law Alliance Can Help

Health Law Alliance represents pharmacies whose PBM audit findings have been referred for fraud, waste, and abuse review, from the first SIU inquiry through an MFCU investigation, an OIG exclusion notice, or a False Claims Act demand, as part of the firm's PBM audit defense practice. The firm evaluates whether a finding still sits inside the ordinary audit appeal track or has already crossed into an investigative posture, and builds the response accordingly. If your pharmacy's audit has been flagged for an FWA referral, contact us for a free, confidential consultation.